Vical Incorporated (VICL)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.99+0.14 (+3.64%)
At close: 4:00 PM EDT
People also watch:
BCRXHEBLGNDNVAXXOMA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open3.88
Prev Close3.85
Bid0.00 x
Ask4.70 x 3000
Day's Range3.85 - 4.00
52wk Range2.80 - 6.20
1y Target EstN/A
Market Cap36.73M
P/E Ratio (ttm)-5.81
Beta1.43
Volume25,950
Avg Vol (3m)61,680
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
    Capital Cube18 days ago

    Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016

    Categories: Yahoo Finance Click here to see latest analysis Vical, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Vical, Inc. – CytRx Corporation, Chimerix, Inc., Agenus Inc., Newlink Genetics Corporation, Merck & Co., Inc., Bristol-Myers Squibb Company and Pfizer Inc. (CYTR-US, CMRX-US, AGEN-US, NLNK-US, MRK-US, ... Read more (Read more...)

  • Associated Press20 days ago

    Vical reports 2Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 14 cents. The drug developer posted revenue of $4.1 million in the period. The company's shares closed at $4.27. A year ago, they ...

  • GlobeNewswire20 days ago

    Vical Reports Second Quarter 2016 Financial Results

    SAN DIEGO, Aug. 09, 2016-- Vical Incorporated today reported financial results for the three and six months ended June 30, 2016. Net loss for the second quarter of 2016 was $1.3 million, or $0.14 per share, ...